Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00238472 |
This study is not being conducted in the United States. The purpose of the study is to evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and albumin excretion.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Type 2 |
Drug: nateglinide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Pilot Study to Evaluate the Effects of Nateglinide Vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion |
Estimated Enrollment: | 24 |
Study Start Date: | May 2003 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CDJN608AIT05 |
Study First Received: | October 12, 2005 |
Last Updated: | June 1, 2006 |
ClinicalTrials.gov Identifier: | NCT00238472 |
Health Authority: | United States: Food and Drug Administration |
Type 2 diabetes nateglinide |
Glyburide Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Nateglinide |
Endocrine System Diseases Endocrinopathy Metabolic disorder Glucose Metabolism Disorders |
Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |